{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:44:26Z","timestamp":1784907866721,"version":"3.55.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2020.00250","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T15:35:53Z","timestamp":1589556953000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation"],"prefix":"10.3389","volume":"11","author":[{"given":"Katharina","family":"J\u00e4hn-Rickert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M.","family":"W\u00f6lfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Jobke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/jbmr.3182","article-title":"Osteoporosis in crisis: it's time to focus on fracture","volume":"32","author":"Binkley","year":"2017","journal-title":"J Bone Min Res."},{"key":"B3","first-page":"108","article-title":"The orthopaedic treatment of fragility fractures","volume":"4","author":"Pietri","year":"2007","journal-title":"Clin Cases Min Bone Metab."},{"key":"B4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/jcb.240550303","article-title":"Osteonal and hemi-Osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone","volume":"55","author":"Parfitt","year":"1994","journal-title":"J Cell Biochem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.ecl.2005.07.009","article-title":"Pathophysiology of age-Related bone loss and osteoporosis","volume":"34","author":"Khosla","year":"2005","journal-title":"Endocrinol Metab Cin Noth Am."},{"key":"B6","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/BOT.0000000000001244","article-title":"An update on the comprehensive approach to fragility fractures","volume":"32","author":"Cohn","year":"2018","journal-title":"J Orthopaedic Trauma."},{"key":"B7","first-page":"92","article-title":"Osteoporosis: a review of treatment options","volume":"43","author":"Tu","year":"2018","journal-title":"P & T."},{"key":"B8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.coph.2016.02.003","article-title":"Osteocytes: the master cells in bone remodelling","volume":"28","author":"Prideaux","year":"2016","journal-title":"Curr Opin Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s11914-017-0403-y","article-title":"Sclerostin: an emerging target for the treatment of cancer-Induced bone disease","volume":"15","author":"McDonald","year":"2017","journal-title":"Curr Osteop Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11914-019-00508-y","article-title":"Inter-site variability of the human osteocyte lacunar network: implications for bone quality","volume":"17","author":"Milovanovic","year":"2019","journal-title":"Curr Osteop Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1084\/jem.20031454","article-title":"Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical bMP antagonist","volume":"199","author":"van Bezooijen","year":"2004","journal-title":"J Exp Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/nm.2452","article-title":"Evidence for osteocyte regulation of bone homeostasis through rANKL expression","volume":"17","author":"Nakashima","year":"2011","journal-title":"Nat Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0002-9343(99)00420-9","article-title":"Apoptosis and osteoporosis","volume":"108","author":"Weinstein","year":"2000","journal-title":"Am J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.bone.2012.01.025","article-title":"Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populations","volume":"50","author":"Kennedy","year":"2012","journal-title":"Bone."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/smll.201602215","article-title":"The formation of calcified nano-Pearls during micropetrosis represents a unique mineralization mechanism in aged human bone","volume":"13","author":"Milovanovic","year":"2017","journal-title":"Small."},{"key":"B16","doi-asserted-by":"publisher","first-page":"R70","DOI":"10.1530\/EC-19-0531","article-title":"Phenomenon of osteocyte lacunar mineralization: indicator of former osteocyte death and a novel marker of impaired bone quality?","volume":"9","author":"Milovanovic","year":"2020","journal-title":"Endocr Connect."},{"key":"B17","doi-asserted-by":"publisher","first-page":"7542","DOI":"10.1021\/nn401360u","article-title":"Osteocytic canalicular networks: morphological implications for altered mechanosensitivity","volume":"7","author":"Milovanovic","year":"2013","journal-title":"ACS Nano."},{"key":"B18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.biomaterials.2014.12.024","article-title":"Multi-level characterization of human femoral cortices and their underlying osteocyte network reveal trends in quality of young, aged, osteoporotic and antiresorptive-treated bone","volume":"45","author":"Milovanovic","year":"2015","journal-title":"Biomaterials."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.3006286","article-title":"Vitamin d deficiency induces early signs of aging in human bone, increasing the risk of fracture","volume":"5","author":"Busse","year":"2013","journal-title":"Sci Trans Med."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3970","article-title":"Long-Term immobilization in elderly females causes a specific pattern of cortical bone and osteocyte deterioration different from postmenopausal osteoporosis","author":"Rolvien","year":"2020","journal-title":"J Bone Min Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/jbmr.149","article-title":"Effects of denosumab on bone histomorphometry : the FREEDOM and STAND studies","volume":"25","author":"Reid","year":"2010","journal-title":"J Bone Min Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Eng J Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Eng J Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","article-title":"Severe spontaneous vertebral fractures after denosumab discontinuation : three case reports","volume":"27","author":"Aubry-Rouzier","year":"2016","journal-title":"Osteop Int."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","article-title":"Rebound-associated vertebral fractures after discontinuation of denosumab - from clinic and biomechanics","volume":"27","author":"Popp","year":"2016","journal-title":"Osteop Int."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s00198-015-3459-5","article-title":"Multiple clinical vertebral fractures following denosumab discontinuation","volume":"27","author":"Anastasilakis","year":"2016","journal-title":"Osteop Int."},{"key":"B27","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/jc.2016-3170","article-title":"Severe rebound-Associated vertebral fractures after denosumab discontinuation: 9 clinical cases report","volume":"102","author":"Lamy","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s00198-016-3553-3","article-title":"Cancel the denosumab holiday","volume":"27","author":"McClung","year":"2016","journal-title":"Osteop Int."},{"key":"B29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1055\/s-0038-1673537","article-title":"S-3 DVO Guidelines 2017 in prophylaxis, diagnosis and therapy of osteoporosis in postmenopausal women und men","volume":"27","author":"Thomasius","year":"2018","journal-title":"Osteologie."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician's guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteop Int."},{"key":"B31","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/jbmr.2340","article-title":"Modifications to nano- and microstructural quality and the effects on mechanical integrity in paget's disease of bone","volume":"30","author":"Zimmermann","year":"2015","journal-title":"J Bone Min Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the aSBMR histomorphometry nomenclature committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J Bone Min Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/j.1474-9726.2010.00633.x","article-title":"Decrease in the osteocyte lacunar density accompanied by hypermineralized lacunar occlusion reveals failure and delay of remodeling in aged human bone","volume":"9","author":"Busse","year":"2010","journal-title":"Aging Cell."},{"key":"B34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1557\/JMR.1992.1564","article-title":"An improved technique for determining hardness and elastic modulus using load and displacement sensing indentation experiments","volume":"7","author":"Oliver","year":"1992","journal-title":"J Mat Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/bonekey.2015.112","article-title":"The fracture mechanics of human bone: influence of disease and treatment","volume":"4","author":"Zimmermann","year":"2015","journal-title":"BoneKEy Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"21072","DOI":"10.1038\/srep21072","article-title":"Intrinsic mechanical behavior of femoral cortical bone in young, osteoporotic and bisphosphonate- treated individuals in low- and high energy fracture conditions","volume":"6","author":"Zimmermann","year":"2016","journal-title":"Sci Rep"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1007\/s00198-006-0135-9","article-title":"The population burden of fractures originates in women with osteopenia, not osteoporosis","volume":"17","author":"Pasco","year":"2006","journal-title":"Osteop Int."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/jbmr.448","article-title":"Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study","volume":"26","author":"Brown","year":"2011","journal-title":"J Bone Min Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1210\/jc.2017-02669","article-title":"Effects of long-Term denosumab on bone histomorphometry and mineralization in women with postmenopausal osteoporosis","volume":"103","author":"Dempster","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"key":"B41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/jbmr.536","article-title":"Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis","volume":"27","author":"McClung","year":"2012","journal-title":"J Bone Min Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteop Int."},{"key":"B43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by eCTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"key":"B44","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00223-017-0386-9","article-title":"Multiple vertebral osteonecroses (Kummell's disease) after 10 years on denosumab: is osteocyte apoptosis to blame?","volume":"103","author":"Biamonte","year":"2018","journal-title":"Calcif Tissue Int."},{"key":"B45","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s00223-017-0357-1","article-title":"Multiple vertebral osteonecroses (Kummell's disease) after 10 years on denosumab: is osteocyte apoptosis to blame?","volume":"102","author":"Maugars","year":"2018","journal-title":"Calcif Tissue Int."}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00250\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T15:35:57Z","timestamp":1589556957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00250\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,15]]},"references-count":45,"alternative-id":["10.3389\/fendo.2020.00250"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2020.00250","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,15]]},"article-number":"250"}}